Vericel Corp. plans to offer and sell common shares in an underwritten public offering.

The company also intends to grant the underwriters an option to buy up to an additional 15% of shares sold in the offering on the same terms and conditions.

Vericel will primarily use the net proceeds to support the commercialization of MACI, expand promotional efforts for Epicel, expand and optimize manufacturing and for other general corporate purposes.

Piper Jaffray & Co. is acting as the sole book runner for the offering.